Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was valued at US$ 1992 million in 2024 and is forecast to a readjusted size of USD 21690 million by 2031 with a CAGR of 41.1% during review period.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

This report is a detailed and comprehensive analysis for global Duchenne Muscular Dystrophy (DMD) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Duchenne Muscular Dystrophy (DMD) Therapeutics market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Duchenne Muscular Dystrophy (DMD) Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Exondys
Emflaza
Translarna

Market segment by Application
Hospitals
Clinics
Home Care

Market segment by players, this report covers
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Duchenne Muscular Dystrophy (DMD) Therapeutics, with revenue, gross margin, and global market share of Duchenne Muscular Dystrophy (DMD) Therapeutics from 2020 to 2025.

Chapter 3, the Duchenne Muscular Dystrophy (DMD) Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Duchenne Muscular Dystrophy (DMD) Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy (DMD) Therapeutics.

Chapter 13, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics research findings and conclusion.